

Ref: FOI/GS/ID 6216

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

30 July 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Psoriasis and Psoriatic Arthritis.

You asked:

- 1. Please detail the number of patients currently prescribed Apremilast with a current primary diagnosis of: a) Psoriasis b) Psoriatic Arthritis?*
- 2. Of the patients prescribed Apremilast in the last 12 months for Psoriasis and Psoriatic Arthritis, what number of patients received treatment with targeted small molecules or biologic therapies* prior to beginning treatment with Apremilast? (*See annex 1 for a list of small molecule/biologic therapies)*
- 3. How many small molecule- and/or biologic-naive patients in the Trust are currently receiving a conventional non-biologic systemic therapy for Psoriasis or a conventional non-biologic disease-modifying anti-rheumatic drug (DMARD) for Psoriatic Arthritis? (e.g. methotrexate)*
- 4. Is CCG prior-approval required for the prescribing of Apremilast? Y/N. If Yes, please tick the system you use: Blueteq /Other .*
- 5. If other, what system do you use?*
- 6. Is Apremilast listed individually or grouped with biologic therapies on the prior-approval form for Psoriasis and Psoriatic Arthritis?*
- 7. Please provide the wording used on the CCG's prior-approval form for the prescribing of Apremilast.*

Annex 1

Abatacept (Orencia®)

Adalimumab (Amgevita®, Humira®, Hyrimoz® or Imraldi®)

Brodalumab (Siliq®)

Certolizumab (Cimzia®)

Etanercept (Benepali®)

Golimumab (Simponi®)

Guselkumab (Tremfya®)

Infliximab (Remicade®)
Ixekizumab (Taltz®)
Risankizumab (Skyrizi®)
Secukinumab (Cosentyx®)
Tildrakizumab (Ilumya®)
Tofacitinib (Xeljanz®)
Ustekinumab (Stelara®)

Trust response:

1.

Psoriasis	Psoriatic Arthritis
Do not treat	1

2.

Psoriasis	Psoriatic Arthritis
Do not treat	1

3.

Therapy	No. of patients receiving the specified therapy	
	Psoriasis	Psoriatic Arthritis
Systemic therapies	Cannot provide	
Disease-modifying anti-rheumatic drugs (DMARDs)		Cannot provide

4. Blueteq.

5. Not applicable

6. **Psoriasis:** Individually **Psoriatic Arthritis:** Individually

7. Please contact Kent and Medway CCG for this information